Antibody Drug Conjugates have been designed as targeted therapy for cancer, and they are relatively new biological drugs. They combine the unique targeting abilities of monoclonal antibodies with the cytotoxic power of small molecule anticancer agents. The combination has been shown to reduce the toxic effects and enhance the therapeutic index of most ADCs.
ADCs are composed of three main components: the antibody, the linker, and the payload. These components work together to form a highly potent cytotoxic agent that is released only when the antibody is inside the target cells. This enables the ADC to reduce off-site toxicity and enhance systemic toxicity, resulting in improved tolerability. ADCs are now used in oncology and neuroscience to treat patients with several types of cancer.
To ensure the targeted delivery of the cytotoxic agent, the monoclonal antibody must be able to penetrate the cancer cell’s surface. This is done by attaching the drug to the monoclonal antibody through chemical linkers. These linkers are either cleavable or non-cleavable. The linker also must be stable enough to allow only the release of the cytotoxic agent when the antibody is inside the target cell. This complex interplay between the three vital components determines the ultimate efficacy of an ADC.
As per statistics provided by Coherent Market Insights, Antibody Drug Conjugates Market is expected to exhibit a CAGR of 14.0% during the forecast period (2021-2028).
ADCs are most commonly employed in oncology to treat cancer. They are a more powerful and safe alternative to conventional chemotherapy. These ADCs are designed to eliminate fast-growing cancer cells, allowing healthy tissue to be spared. ADCs are now used to treat cancers of many different types, including glioblastoma, refractory or relapsed diffuse large B-cell lymphoma, acute myeloid leukemia, and others.
These ADCs can also be combined with other chemotherapy drugs to improve the effectiveness of the treatment. ADCs are a promising new class of biopharmaceuticals. They are currently being tested in more than nine clinical trials. ADCs are also being evaluated in a number of pre-clinical studies.
The monoclonal antibody recognizes the surface antigen on the cancer cells and targets the receptor on the cancer cell, allowing the cytotoxic agent to enter the cell and kill it. The monoclonal antibody must be non-immunogenic and must be capable of internalization into the cancer cell. Once the antibody has entered the cancer cell, it binds to the cancer’s receptor, which in turn triggers a series of steps that lead to rapid cytotoxic cell death. The monoclonal antibody must be specific to the type of cancer being treated. The ADC can also be designed to discriminate between cancer and healthy tissue.
Unlike other cytotoxic agents, ADCs are highly selective. The combination of a cytotoxic agent and a monoclonal antibody gives the ADC a high theoretical curative effect. Antibody-drug conjugates are safer than free cytotoxic agents. They can be administered systemically and have lower side effects than traditional chemotherapies.
The first generation of ADCs, known as immunotoxins, were used in glioma patients. They were derived from natural products, such as tyrosine kinase inhibitors and cytokines. The molecular weight of these toxins is often quite large, making them difficult to deliver to a cancer cell. However, more recently developed ADCs have shown promising results in glioma patients.
A number of companies have developed antibody drug conjugates (ADCs) in the past few years. These biopharmaceuticals are designed to target cancer cells and spare healthy cells. This is important as good ADC must be effective in targeting a tumor while not causing collateral damage. ADCs are molecular complexes containing antibodies and a cytotoxic payload.
